Abstract:Objective: Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia. The efficacy as well as safety of aripiprazole in Western populations has been described. The objective of this study is to investigate the efficacy, safety, and tolerability of aripiprazole and risperidone in Chinese Han schizophrenia subjects in mainland China. Method: The 6-week, double-blind, randomized, parallel study was conducted in 5 medical centers in mainland China from November 2007 to March 2011. A total of 279 subjects with a primary DSM-IV diagnosis of schizophrenia were randomly assigned (with a randomization ratio of 1: 1) to aripiprazole (n = 139) or risperidone (n = 140). Efficacy measurements included the Positive and Negative Syndrome Scale (PANSS) total, positive, negative and general psychopathology subscale scores, and Clinical Global Impressions-Severity of Illness (CGI-S), and Improvement scale scores. Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events were also assessed as measures of safety and tolerability. Results: Both the aripiprazole and risperidone groups showed statistically significant improvement of PANSS total, positive, negative, general psychopathology subscale scores, and CGI-S scores from baseline to the endpoint (all p < 0.01). Significant improvement was noted in the first week for both treatment groups. There were no significant differences in efficacy measurements between the two treatment groups. Mean change of PANSS total scores from baseline to the endpoint was -26.8 +/- 18.1 for aripiprazole and -30.0 +/- 17.7 for risperidone, (p = 0.1475). The responder rate was 71% (n = 99) and 76% (n = 107) for aripiprazole and risperidone, respectively, (p = 0.323). The incidences of EPS were similar in the aripiprazole (25%, n = 35) and risperidone groups (24%, n = 34), respectively (p = 0.757). No clinically meaningful effects on QTc interval, QRS duration, or PR interval were observed in either treatment groups. However, the incidence of clinically significant weight gain (p = 0.0118) and hyperprolactinemia (p < 0.001) in the aripiprazole group was significantly lower than in the risperidone group. Conclusion: The study demonstrated that aripiprazole, as well as risperidone, had rapid and persistent efficacy for psychotic symptoms from the first week of therapy. There may be poor efficacy for aripiprazole compared with risperidone for overall improvement, but there were no significant differences in this study. Aripiprazole showed good tolerability with less weight gain and hyperprolactinemia compared with risperidone. The overall efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects were similar to that reported in Western populations. (C) 2014 Published by Elsevier B.V.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

A double blinded multicenter clinical trial for evaluating the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia

Safety and Efficacy of Paliperidone Palmitate 1-Month Formulation in Chinese Patients with Schizophrenia: a 25-Week, Open-Label, Multicenter, Phase IV Study

Efficacy and Safety of Paliperidone Palmitate or Long-acting Injectable Risperidone in Patients with Schizophrenia

Critical Evaluation of Paliperidone in the Treatment of Schizophrenia in Chinese Patients: a Systematic Literature Review.

A Randomized, 13-Week Study Assessing the Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients

Long-term Efficacy and Safety of Paliperidone Palmitate Once-Monthly in Chinese Patients with Recent-Onset Schizophrenia

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.

Double-blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia

Once-monthly Injection of Paliperidone Palmitate in Patients with Recently Diagnosed and Chronic Schizophrenia: a Post-Hoc Comparison of Efficacy and Safety

Pharmacokinetics and Tolerability of Paliperidone Palmitate Injection in Chinese Subjects

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Efficacy and safety of long-acting injectable risperidone(RLAI) in 40 patients with schizophrenia

Clinical outcomes of paliperidone long-acting injection in patients with schizophrenia: a 1-year retrospective cohort study

A clinical controlled study on schizophrenia treated with paliperidone-ER and risperidone

The Efficacy and Safety of Risperidone Long-Acting Injectable for the Treatment of Schizophrenia

A Subgroup Analysis of Chinese Patients Switched to Paliperidone Palmitate One-Month Injectable by Prior Oral Antipsychotic Treatment

A Comparative Study of Aripiprazole Versus Risperdal in Patients with Schizophrenia